| Literature DB >> 22844589 |
Eugenio Volpi1, Luca Bernardini, Anna Maria Ferrero.
Abstract
Introduction. We retrospectively report our experience with the utilization of an original procedure for total laparoscopic hysterectomy based on completely retrograde and retroperitoneal technique for surgical staging and treatment of the endometrial cancer. The surgical, financial, and oncological advantages are here discussed. Methods. The technique used here has been based on a combination of a retroperitoneal approach with a retrograde and lateral dissection of the bladder and retrograde culdotomy with variable resection of parametrium. No disposable instruments and no uterine manipulator were utilized. Results. Intraoperative and postoperative complications were observed in 10% of the cases overall. Operative time length and mean haemoglobin drop value results were 129 min and 125 mL, respectively. Most patients were dismissed on days 3-5 from the hospital. Seventy-eight percent of the patients were alive with no evidence of disease at mean followup of 49 months. Conclusions. Our original laparoscopic technique is based on a retroperitoneal approach in order to rapidly control main uterine vessels coagulation, constantly check the ureter, and eventually decide type and site of lymph nodes removal. This procedure has important cost saving implications and the avoidance of uterine manipulator is of matter in case such as these of uterine malignancy.Entities:
Year: 2012 PMID: 22844589 PMCID: PMC3403385 DOI: 10.1155/2012/263850
Source DB: PubMed Journal: Int J Surg Oncol ISSN: 2090-1402
Patients characteristics.
| Patient's profile | |
|---|---|
| Number of cases | 95 |
| Age (years) mean (range) | 63.46 (43–84) |
| BMI mean (range) | 29.64 (20–46) |
| Other pathologies | |
| Hypertension | 60 |
| Diabetes | 13 |
| Thyroid | 9 |
| Other | 13 |
| Total (%) | 95 (100%) |
| Previous surgeries | 51 |
| Histology | |
| Endometrioid | 67 |
| Adenosquamous | 8 |
| Serous-papillary | 6 |
| Villous-glandular | 5 |
| Undifferentiated | 5 |
| Mucinous | 2 |
| Carcinosquamous | 1 |
| Clear cell | 1 |
| Grading | |
| G1 | 33 |
| G2 | 43 |
| G3 | 19 |
| Myometrial invasion | |
| No invasion | 6 |
| <50% | 50 |
| >50% | 39 |
| FIGO Staging | |
| IA | 51 |
| IB | 26 |
| II | 3 |
| IIIA | 5 |
| IIIC1 | 7 |
| IIIC2 | 3 |
| Positive washing cytology | 12 (6/12 myom.invasion < 50%) |
Perioperative data.
| Number of cases | |
|---|---|
| Hysterectomy + bilat. annessiectomy | 95 |
|
| 74 |
|
| 21 |
| Operative time (min) | 129.47 (60–240) |
| EBL (mL)∗ | 125.15 (100–300) |
| Pelvic lymphadenectomy | 65 |
| Mean number of pelvic lymph removed | 10.25 (1–28) |
| Para-aortic lymphadenectomy and omentectomy | 13 |
| Mean number of hospitalization days | 3.5 (2–5) |
| Intraoperative complications (2 blood transfusions, 3 ureteral injuries) | 5.2% (5/95) |
| Postoperative complications (fistula, lymphocyst, ascess, renal dilatation, hematoma) | 5.2% (5/95) |
*EBL: bleeding loss.
Adjuvant therapy, followup, and survival.
| Number of cases | |
|---|---|
| Adjuvant radiotherapy | 20 |
| Adjuvant chemotherapy | 9 |
| No adjuvant therapy | 66 |
| Mean followup (months) | 49.09 (4–140) |
| Lost | 6 |
| NED∗ | 75 |
| ED° | 1 |
| Deaths | 13 |
| Recurrences | 13 (12 deaths + 1 ED) |
|
| 4 |
|
| 6 |
|
| 3 |
| Disease-free interval (months) | 15 (7–34) |
∗NED: no evidence of disease.
°ED: evidence of disease.